Ongoing Phase 3 Study Finds Daratumumab Improves Survival in Advanced Multiple Myeloma Patients
Genmab has announced positive results from its Phase 3 POLLUX study investigating the efficacy of daratumumab, in combination with lenalidomide and dexamethasone, to treat patients with relapsed or refractory multiple myeloma, compared to lenalidomide and dexamethasone alone. The ongoing trial met its primary endpoint, with treated patients demonstrating improved progression-free survival, indicating that the…